Last reviewed · How we verify

Prolia — Competitive Intelligence Brief

Prolia (DENOSUMAB) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RANK Ligand Inhibitor [EPC]. Area: Oncology.

marketed RANK Ligand Inhibitor [EPC] Tumor necrosis factor ligand superfamily member 11 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Prolia (DENOSUMAB) — Amgen. Prolia works by blocking a protein that breaks down bone.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Prolia TARGET DENOSUMAB Amgen marketed RANK Ligand Inhibitor [EPC] Tumor necrosis factor ligand superfamily member 11 2010-01-01
BONCRESA DENOSUMAB-MOBZ AMNEAL PHARMS LLC marketed RANK Ligand Inhibitor [EPC] RANKL
JUBBONTI DENOSUMAB-BBDZ SANDOZ INC marketed RANK Ligand Inhibitor [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RANK Ligand Inhibitor [EPC] class)

  1. AMNEAL PHARMS LLC · 1 drug in this class
  2. Amgen · 1 drug in this class
  3. SANDOZ INC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prolia — Competitive Intelligence Brief. https://druglandscape.com/ci/denosumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: